The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

被引:3
作者
Tie, Xiaowei [1 ]
Wang, Jin [1 ]
Wang, Yong [1 ]
Fu, Baobao [1 ]
Wang, Chenchen [1 ]
Li, Xiaomin [2 ]
Jia, Qianqian [1 ]
Wang, Fang [1 ]
Chen, Simeng [1 ]
Zhang, Yanshun [1 ,3 ]
机构
[1] Anhui Univ Sci & Technol, Affiliated Hosp 1, Hefei, Anhui, Peoples R China
[2] Bozhou Peoples Hosp, Bozhou, Qiaocheng, Peoples R China
[3] Anhui Univ Sci & Technol, Affiliated Hosp 1, Hefei 232000, Anhui, Peoples R China
关键词
lung adenocarcinoma; metastasis pattern; overall survival; SEER; CANCER; STATISTICS; BONE;
D O I
10.1097/MD.0000000000033297
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of various metastases patterns on the prognosis of lung adenocarcinoma (AD) remains unknown. The purpose of our retrospective study is to determine whether various metastases patterns have a prognostic impact on patients with organ metastatic lung AD. Patient data was extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was chosen for the evaluation of overall survival (OS) rate. Univariable and multivariable Cox regression analyses were conducted to evaluate independent prognostic factors. In the SEER database, 12,228 patients with IV lung AD were retrieved in total. And 78.78% of those patients (9633/12,228) suffered from one of brain, lung, liver or bone metastasis due to disease progression. It was found that the most common site in patients with metastatic lung AD was brain (21.20%), and the least common site of metastasis was liver (3.50%). Patients who suffered single lung metastatic showed relatively good OS, and the median survival time was 11 months (95% CI 0.470-0.516). For those with 2 metastatic sites, data analysis suggested that the median survival times of patients with bone and lung metastasis (10 months; 95% CI 0.469-0.542) were better than others. For those with 3 metastatic sites, data analysis suggested that metastatic pattern had no effect on the OS. Brain is the most common single metastasis site of lung AD. Compared with the other 3 metastatic sites, patients with lung metastasis had better survival results. Deeper knowledge of metastatic patterns will help doctors to better understand the prognosis and formulate more appropriate treatment plans.
引用
收藏
页数:7
相关论文
共 21 条
  • [1] Concepcion CP, 2021, CANCER RES, V81
  • [2] Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
    D'Antonio, Chiara
    Passaro, Antonio
    Gori, Bruno
    Del Signore, Ester
    Migliorino, Maria Rita
    Ricciardi, Serena
    Fulvi, Alberto
    de Marinis, Filippo
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (03) : 101 - 114
  • [3] The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma
    Daugaard, Iben
    Knudsen, Alice
    Kjeldsen, Tina E.
    Hager, Henrik
    Hansen, Lise Lotte
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (03) : 484 - 491
  • [4] Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Akerley, Wallace
    Bazhenova, Lyudmila A.
    Borghaei, Hossein
    Camidge, David Ross
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Demmy, Todd L.
    Dilling, Thomas J.
    Dobelbower, M. Chris
    Govindan, Ramaswamy
    Grannis, Frederic W., Jr.
    Horn, Leora
    Jahan, Thierry M.
    Komaki, Ritsuko
    Krug, Lee M.
    Lackner, Rudy P.
    Lanuti, Michael
    Lilenbaum, Rogerio
    Lin, Jules
    Loo, Billy W., Jr.
    Martins, Renato
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Rohren, Eric
    Schild, Steven E.
    Shapiro, Theresa A.
    Swanson, Scott J.
    Tauer, Kurt
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (05): : 515 - 524
  • [5] Targeting of SGK1 by miR-576-3p Inhibits Lung Adenocarcinoma Migration and Invasion
    Greenawalt, Evan J.
    Edmonds, Mick D.
    Jain, Neha
    Adams, Clare M.
    Mitra, Ramkrishna
    Eischen, Christine M.
    [J]. MOLECULAR CANCER RESEARCH, 2019, 17 (01) : 289 - 298
  • [6] Lung cancer: current therapies and new targeted treatments
    Hirsch, Fred R.
    Scagliotti, Giorgio V.
    Mulshine, James L.
    Kwon, Regina
    Curran, Walter J.
    Wu, Yi-Long
    Paz-Ares, Luis
    [J]. LANCET, 2017, 389 (10066) : 299 - 311
  • [7] UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells
    Ho, Jhih-Yun
    Lu, Hsin-Ying
    Cheng, Hsing-Hsien
    Kuo, Yu-Chieh
    Lee, Yu-Lin Amy
    Cheng, Chia-Hsiung
    [J]. CELLULAR ONCOLOGY, 2021, 44 (06) : 1325 - 1338
  • [8] Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
  • [9] New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study
    Klikovits, Thomas
    Lohinai, Zoltan
    Fabian, Katalin
    Gyulai, Marton
    Szilasi, Maria
    Varga, Judit
    Baranya, Erika
    Pipek, Orsolya
    Csabai, Istvan
    Szallasi, Zoltan
    Timar, Jozsef
    Hoda, Mir Alireza
    Laszlo, Viktoria
    Hegedus, Balazs
    Renyi-Vamos, Ferenc
    Klepetko, Walter
    Ostoros, Gyula
    Doeme, Balazs
    Moldvay, Judit
    [J]. LUNG CANCER, 2018, 126 : 139 - 148
  • [10] The synergistic effect of propofol and ulinastatin suppressed the viability of the human lung adenocarcinoma epithelial A549 cell line
    Li, Ping
    Guo, Peipei
    Lin, Chunshui
    He, Murong
    Zhu, Xiaoqing
    Liu, Chuan
    Tang, Jing
    Wang, Wei
    Liang, Weidong
    [J]. ONCOLOGY LETTERS, 2018, 16 (04) : 5191 - 5199